Focus on Immunizations

Back to articles

Shingles vaccine: Is a booster shot on the horizon?

KEY POINT

In a follow-up of a 4-year herpes zoster vaccine live (Zostavax—Merck) trial conducted in a cohort of patients monitored for an additional 3 years, zoster vaccine efficacy decreased over time, but was statistically significant for herpes zoster incidence and burden of illness through year 5.